NewsEpisurf Medical Interim Report 1 April – 30 June 2017

Second quarter 2017, compared to 2016, Group
» Group net sales increased by 33% to SEK 622,897 (469,380)
» Other operating income including capitalized development expenditure amounted to SEK 607,140 (381,298)
» Loss before tax amounted to SEK –12,990,707 (–16,473,988)
» Earnings per share (weighted average) amounted to SEK –0.45 (–1.03)

Significant events during the second quarter
» Episurf Medical announced that the 50th implantation in Germany of the Episealer® knee implant was performed
» Episurf Medical obtained further granted patents in Australia, US and Europe
» Episurf Medical strengthened the company’s management group
» Episurf Medical reached milestone of 200 implants
» Episurf Medical continued its communication with the US Food and Drug Administration (FDA)
» Episurf Medical’s Board named Pål Ryfors new CEO and appointed Veronica Wallin as new CFO
» Episurf Medical appointed Dr Michael Manley Special Advisor for the US strategy

Significant events after the second quarter
» Dennis D. Stripe re-assumed the position as non-executive chairman of the board
» Case-report with clinical data of Episealer® patient was published
» Another preclinical paper on the Episealer® Implant published
» Episurf Medical became an approved supplier to Spire Healthcare, one of the UK’s largest Independ­ent hospital providers
» Episurf Medical reported a brief clinical update
» Management group changes in Episurf Medical were announced
» Episurf Medical reached milestone of 250 implants

For more information, please contact:
Pål Ryfors, CEO, Episurf Medical
Tel: +46 (0) 709 62 36 69